Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allo MOG CAR-Treg
- Development stage
- Preclinical
- Lead developer
- PolTREG
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Allo MOG CAR-Treg is an allogeneic, gene-edited chimeric antigen receptor regulatory T-cell (CAR-Treg) therapy being developed by PolTREG for the treatment of neuroinflammatory and neurodegenerative diseases. The therapy utilizes regulatory T-cells (Tregs) from healthy donors that are engineered to express a CAR specific for Myelin Oligodendrocyte Glycoprotein (MOG), a protein primarily expressed on the surface of myelinating oligodendrocytes in the central nervous system. By targeting MOG, these cells are designed to localize to the brain and spinal cord to suppress localized autoimmune responses and promote tissue repair. The Multi-Edit aspect refers to the use of gene-editing technology to create an off-the-shelf product by reducing the risk of graft-versus-host disease and immune rejection. It is currently in preclinical development for Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and MOG Antibody Disease (MOGAD).
- Other names
- Multi-Edit/Allo MOG CAR-TregAllogeneic MOG CAR-TregMulti-Edit/Allo MOG CAR-Treg: Neuro Basket
02
Targets
MOG (Myelin oligodendrocyte glycoprotein)
Beyond the preview
Go deeper on Allo MOG CAR-Treg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allo MOG CAR-Treg.